参麦注射液联合TE化疗方案治疗进展期乳腺癌的临床观察研究
The clinical effect of TE chemotherapy regime, with Shenmai injection in the treatment of advanced breast cancer
-
摘要: 目的 探讨参麦注射液联合新辅助化疗TE方案治疗乳腺癌的疗效和对乳腺癌患者生活质量的影响。 方法 我院收治的22例经病理证实的进展期乳腺癌患者,年龄34~72岁,随机分为试验组(参麦注射液联合TE治疗组)和对照组(单纯用TE化疗组)。对照组未给予任何中药注射液。对22例进展期乳腺癌患者的疗效、血常规指标及不良反应进行观察比较与分析,应用SPSS10.0统计软件进行统计学处理。 结果 可评价疗效病例22例,其中治疗组有效率(CR+PR) 54.55%,对照组有效率63.64%,两组之间差异无统计学意义(P＞0.05);临床获益率治疗组81.82%,对照组72.73%,两组之间差异无统计学意义(P＞0.05)。两组血液系统的不良反应与对照组相比,结果有统计学意义(P<0.05)。其他不良反应的发生率相似,两组差异无显著性(P＞0.05)。 结论 参麦注射液联合TE方案治疗乳腺癌疗效肯定,耐受性良好,加用参麦注射液可以改善肿瘤患者的生存质量,减轻化疗所致的血液学毒性及非血液学毒性,临床可推广应用。Abstract: Objective To investigate the efficacy of Shenmai injection combined TE chemotherapy regime in the treatment of breast cancer and the influence to the quality of life in breast cancer patient. Methods 22 patients with pathologically confirmed advanced breast cancer aged from 34 to 72 were randomly divided into experimental group (TE plus Shenmai injection treatment group) and the control group (only with TE chemotherapy group). The efficacy ,side effects and blood indices were observed and analyzed. All patients received two or more cycles of treatment. SPSS10.0 statistical software was used to statistical analysis. Results 22 cases could be evaluated.The effective rate of treatment group (CR+PR) was 54.55%, and the rate of control group was 63.64%. There was no significant difference between two groups (P>0.05); clinical benefit rate was 81.82% in treatment group, and 72.73% in control group, which had no significant difference between groups (P>0.05). The main adverse events in both groups were from the blood system. compared with the control group, which had statistically significant (P<0.05) between two groups. Other adverse reactions had the similar incidence in two groups and had not statistically significant (P>0.05). Conclusion TE Shenmai injection in the treatment of breast cancer was effective and well tolerated, plus Shenmai injection could improve the quality of life in cancer patients, reduce the chemotherapy-induced hematological toxicity and non-hematologic toxicity.
-
Key words:
- Shenmai injection /
- breast cancer /
- TE program /
- clinical observation
-
[1] 李佩文,李 学.中医肿瘤临床手册[M].上海:上海科学技术出版社,2006:145. [2] Mass HB. Endocrine therapy for advanced breast cancer [J].Breast Cancer Res Treat,1992,21:15. [3] 赵 强,常 英,潘 靖.云硒冲剂对乳腺癌术后化疗患者免疫功能的影响[J].药学实践杂志. 2004,22(3):156. [4] 赵晓辉,郝春芳,佟仲生.紫杉醇单药每周方案治疗老年转移性乳腺癌的临床疗效观察[J].中华乳腺病杂志,2009,3(5):17. [5] 张代钊,余桂清,李佩文.癌症放化疗副反应的中医药防治研究[J].中医杂志,1994,35 (8):498. [6] 陈小红,高瑞兰,徐卫红,等.人参皂甙对红系,粒单系,巨核系细胞株的增殖及转录因子的诱导作用[J].中国中西医结合杂志,2001,21(1) :40. [7] 冯培芳,刘鲁明,沈玉英,等.参麦注射液对晚期癌症患者sIL-2R、LAK及NK细胞活性影响[J].中国中西医结合杂志,1995,15 (2):87. [8] 钱 华,林胜友,刘鲁明,等.参麦注射液对肿瘤化疗的减毒作用[J].浙江中医学院学报,1995,19 (2):32. -
点击查看大图
计量
- 文章访问数: 3004
- HTML全文浏览量: 220
- PDF下载量: 173
- 被引次数: 0
下载:
